Evidence map›Paper›PMID 36563744›Full record

ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2023

Penicillin allergy delabeling: Opportunities for implementation and dissemination.

Upeka Samarakoon, John Accarino, Alysse G Wurcel, Jordon Jaggers, Allen Judd, Kimberly G Blumenthal

Abstract readReview
In one paragraph

Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Quality and Consistency of Penicillin Allergy Delabelling Guidelines: A Systematic Review.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Pooled it
  2. Penicillin allergies and community antibiotic prescriptions: A secondary analysis of prescribing choices in six family medicine clinics in southern Ontario, 2018-2019.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026
    Article
  3. Article
  4. Article
  5. Outpatient penicillin allergy de-labeling in primary care-whom to target.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Penicillin allergy delabeling in long-term care facilities: if not now, then when?Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Barriers to penicillin allergy de-labeling in the inpatient and outpatient settings: a qualitative study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Upeka SamarakoonDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
John AccarinoDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Alysse G WurcelDivision of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts.
Jordon JaggersDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Allen JuddDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
Kimberly G BlumenthalDivision of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: kblumenthal@mgh.harvard.edu.

Funding

Unlocking Access to HCV Testing in Jail: Stakeholder Involvement in Research Is the Missing KeyK08HS026008 · AHRQ · TUFTS MEDICAL CENTER · PI WURCEL, ALYSSE GAIL · 2020 to 2022
$450k
AHRQ HHS K08 HS026008
6 · The paper itself

Abstract

Although existing as a safety measure to prevent iatrogenic harm, unconfirmed penicillin allergy labels have a negative impact on personal and public health. One downstream effect of unconfirmed penicillin allergy is the continued emergence and transmission of resistant bacteria and their associated health care costs. Recognizing the consequences of inaccurate penicillin allergy labels, professional and public health organizations have started promoting the adoption of proactive penicillin allergy evaluations, with the ultimate goal of removing the penicillin allergy label when the allergy is disproved, also known as penicillin allergy "delabeling." A penicillin allergy evaluation includes a comprehensive allergy history often followed by drug challenge, sometimes with preceding skin testing. Currently, penicillin allergy delabeling is largely carried out by allergy specialists in outpatient settings. Penicillin allergy delabeling is performed on inpatients, albeit rarely, often at the time of need, as a point-of-care procedure. Access to penicillin allergy evaluation services is limited. Recent studies demonstrate the feasibility of expanding penicillin allergy evaluations and delabeling to internists, pediatricians, emergency medicine physicians, infectious diseases specialists, and clinical pharmacists. However, reducing the impact of mislabeled penicillin allergy will require comprehensive efforts and new investments. In this review, we summarize the current practices of penicillin allergy delabeling and discuss expansion opportunities for penicillin allergy delabeling as quality improvement.

Indexed as

Drug HypersensitivityHypersensitivityPhysiciansAnti-Bacterial AgentsHumansPenicillinsSkin TestsAnti-Bacterial AgentsPenicillins

Identifiers

PMID36563744
PMCPMC11949300

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.